[Autologous bone marrow transplantation in children]

Area of Science:

• Pediatric Oncology
• Hematology
• Cancer Transplantation

Background:

• Autologous bone marrow transplantation (ABMT) is a critical treatment for pediatric cancers with limited response to standard chemotherapy and irradiation.
• Megatherapy combined with ABMT has demonstrated significant advantages in treating specific childhood malignancies.

Purpose of the Study:

• To evaluate the efficacy and necessity of autologous bone marrow transplantation in pediatric cancer patients.
• To estimate the annual demand for ABMT in Denmark based on treatment outcomes.

Main Methods:

• Review of treatment outcomes for conventional therapy versus ABMT in pediatric cancers.
• Analysis of patient response rates for various cancer types including B-cell lymphoma, leukemia relapse, neuroblastoma, germ cell tumors, Wilms' tumor, and sarcomas.
• Estimation of annual ABMT needs based on established treatment protocols and patient populations.

Main Results:

• ABMT combined with megatherapy has shown substantial benefits in B-cell lymphoma, relapsed leukemia, disseminated neuroblastoma, and germ cell tumors.
• Limited but notable use of ABMT has been observed in Wilms' tumor, rhabdomyosarcoma, osteosarcoma, and Ewing's sarcoma, particularly in cases of partial response or relapse.
• The estimated annual requirement for ABMT in Denmark is 24 transplantations, considering optimal outcomes from both conventional and ABMT approaches.

Conclusions:

• Autologous bone marrow transplantation is a valuable therapeutic option for specific pediatric cancers that are refractory to standard treatments.
• Further application of ABMT may be warranted for certain pediatric solid tumors with partial response or relapse.
• A defined need for 24 autologous bone marrow transplantations per year in Denmark highlights its role in pediatric cancer care.